A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas

•PankoMab-GEX is a glyco-optimised humanised IgG1 monoclonal antibody.•It binds to a glycopeptide epitope on tumour-associated MUC1.•Glyco-optimisation leads to enhanced tumour cell killing (antibody-dependent cell cytotoxicity, apoptosis).•Phase I trial: PankoMab-GEX was safe, well tolerated, and of low immunogenicity.•Anti-tumour activity in advanced disease, particularly in OvCa, was observed.